For type 2 diabetes mellitus. ANDA 77095, held by Aurobindo. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 77095 (Metformin Hydrochloride), held by Aurobindo, was first approved by FDA on Jan 14, 2005, with 8 approved supplements and 0 published complete response letters.
Metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 14, 2005 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride850MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride1GM · tablet;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 35Labeling · Standard review | Approved | None posted |
| Mar 29, 2024 | Supplement 32Manufacturing | Approved | None posted |
| Feb 14, 2019 | Supplement 24Labeling · Standard review | Approved | None posted |
| Feb 14, 2019 | Supplement 23Labeling · Standard review | Approved | None posted |
| May 12, 2009 | Supplement 8Labeling | Approved | None posted |
| May 12, 2009 | Supplement 6Labeling | Approved | None posted |
| Oct 29, 2008 | Supplement 9Labeling | Approved | None posted |
| Mar 16, 2007 | Supplement 2Labeling | Approved | None posted |
| Jan 14, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters